# BriaCell Therapeutics Corp.: overview BCTX · Nasdaq · CIK 1610820 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jul 31 Pages: [Overview](/companies/bctx.md) · [Financials](/companies/bctx/financials.md) · [Filings](/companies/bctx/filings.md) · [Insiders](/companies/bctx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-07-31) | Q1 FY2025 (2024-10-31) | Q2 FY2025 (2025-01-31) | Q3 FY2025 (2025-04-30) | Q4 FY2025 (2025-07-31) | Q1 FY2026 (2025-10-31) | Q2 FY2026 (2026-01-31) | Q3 FY2026 (2026-04-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [(32.67)](/filings/0001493152-25-027240.md) | [(23.31)](/filings/0001493152-26-009557.md) | [(16.42)](/filings/0001493152-26-027928.md) | not reported | [(4.35)](/filings/0001493152-25-027240.md) | [(2.58)](/filings/0001493152-26-009557.md) | [(0.99)](/filings/0001493152-26-027928.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-07-31) | FY2022 (2022-07-31) | FY2023 (2023-07-31) | FY2024 (2024-07-31) | FY2025 (2025-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [(1.73)](/filings/0001493152-23-038298.md) | [(1.30)](/filings/0001493152-24-042743.md) | [(43.68)](/filings/0001493152-25-018212.md) | [(62.19)](/filings/0001493152-25-018212.md) | | Free cash flow | $m | not reported | not reported | not reported | [(24.6)](/filings/0001493152-25-018212.md) | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bctx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $716.8k | 895,864 | | Reduced −152,895 | | [Cable Car Capital, LP](/funds/1699575.md) | 2026-06-30 | $702.5k | 216,821 | | Unchanged | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $477.6k | 536,600 | | Unchanged | | [Cable Car Capital, LP](/funds/1699575.md) | 2026-06-30 | $286.5k | 321,898 | | Unchanged | | [Empery Asset Management, LP](/funds/1469336.md) | 2026-06-30 | $267.0k | 300,000 | | Unchanged | | [SABBY MANAGEMENT, LLC](/funds/1535610.md) | 2026-06-30 | $261.5k | 80,721 | | Added +6,806 | | [IRIDIAN ASSET MANAGEMENT LLC/CT](/funds/1033427.md) | 2026-06-30 | $210.6k | 65,000 | | Unchanged | | [MYDA Advisors LLC](/funds/1589689.md) | 2026-06-30 | $174.3k | 195,821 | | Reduced −4,179 | | [SABBY MANAGEMENT, LLC](/funds/1535610.md) | 2026-06-30 | $169.4k | 190,383 | | Reduced −190,303 | | [HEIGHTS CAPITAL MANAGEMENT, INC](/funds/1081698.md) | 2026-06-30 | $149.3k | 186,582 | | Reduced −113,418 | ## Recent filings [All 321 filings](/companies/bctx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-06-26 | 16:05 ET | [8-K](/filings/0001493152-26-030286.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-030286 | | 2026-06-09 | 16:06 ET | [10-Q](/filings/0001493152-26-027928.md) | Quarterly report, period 2026-04-30 | 0001493152-26-027928 | | 2026-06-03 | 21:32 ET | [8-K](/filings/0001493152-26-026953.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-026953 | | 2026-03-31 | 16:10 ET | [8-K](/filings/0001493152-26-014156.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-014156 | | 2026-03-10 | 17:08 ET | [10-Q](/filings/0001493152-26-009557.md) | Quarterly report, period 2026-01-31 | 0001493152-26-009557 | | 2026-03-09 | 16:52 ET | [8-K](/filings/0001493152-26-009382.md) | 5.07 Shareholder vote results | 0001493152-26-009382 | | 2026-02-20 | 16:00 ET | [8-K](/filings/0001493152-26-007587.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-007587 | | 2026-02-12 | 16:00 ET | [DEF 14A](/filings/0001493152-26-006390.md) | Proxy statement, period 2026-02-12 | 0001493152-26-006390 | | 2026-01-15 | 16:15 ET | [8-K](/filings/0001493152-26-002430.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-002430 | | 2025-12-29 | 16:05 ET | [8-K](/filings/0001493152-25-029363.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-25-029363 | ## Latest annual report [Form 10-K for the fiscal year ended Jul 31, 2025](/filings/0001493152-25-018212.md), filed Oct 16, 2025. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1610820 - Tickers: BCTX, BCTXL, BCTXZ - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: A1 - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.